Ayvakit® (avapritinib) – New indication
June 16, 2021 - Blueprint Medicines announced the FDA approval of Ayvakit (avapritinib), for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).
Top